



RPG LIFE SCIENCES LIMITED
Regd. Off.: RPG House
463, Dr. Annie Besant Road
Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375
Fax: +91-22-24970127
Email: info@rpglifesciences.com
www.rpglifesciences.com
CIN : L24232MH2007PLC169354

October 17, 2025

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Outcome of Board Meeting of the Company held on October 17, 2025.

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Friday, October 17, 2025, inter-alia, unanimously approved/took on record, the following:

1. Financial Results

Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025. The said unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. Resignation of Key Managerial Personnel

Resignation of Mr. Vishal Shah from the position of Chief Financial Officer and Key Managerial Personnel of the Company with effect from close of business hours on October 23, 2025, for personal reasons as stated in his resignation letter enclosed as Annexure B.

The details required as per SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed as Annexure - A.

The Company is in the process of identifying a suitable candidate for the said position and shall inform the Stock Exchanges once the vacancy is filled up.

The meeting commenced at 03:00 p.m. and concluded at 5.30 p.m.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For RPG Life Sciences Limited

Rajesh Shirambekar
Head – Legal & Company Secretary
Encl.- as above

Annexure – A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

1.	Reason for change viz., appointment, resignation, removal, death or otherwise.	Resignation as Chief Financial Officer due to personal reasons.
2.	Date of appointment / cessation (as applicable) and term of appointment	Effective from close of business hours on October 23, 2025.
3.	Brief Profile (in case of appointment)	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Annexure -B

October 17, 2025

To,

Mr. Ashok Nair

Managing Director,

RPG Life Sciences Limited

Subject: Resignation from the position of Chief Financial Officer

Dear Sir,

I hereby tender my resignation from the position of Chief Financial Officer of RPG Life Sciences Limited due to personal reasons. I request to be relieved of my duties from close of business hours of October 23, 2025.


It has been a privilege to serve the Company in this capacity and I take pride in having been part of the Company's transformation journey. I am grateful for the opportunities given for professional growth, the trust placed in me, the collaborative experience and knowledge gained during my tenure.

I sincerely thank the Board of Directors, Management and Colleagues for their invaluable guidance and unwavering support extended to me. I wish the Company continued success in all its future endeavours.

Please arrange to make the necessary filings with the Ministry of Corporate Affairs and Stock Exchanges to formally intimate my resignation within the prescribed time limit.

Thanking You.

Yours sincerely,



Vishal Shah

Chief Financial Officer

RPG Life Sciences Limited

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited (the "Company") for the quarter ended September 30, 2025 and year to date from April 1, 2025 to September 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

Aruna

per Aruna Kumaraswamy
Partner
Membership No.: 219350
UDIN: 25219350BMMAE8858
Place: Mumbai
Date: October 17, 2025



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2025

Particulars	(Rs. in Lakhs)					
	Quarter ended			Six months ended		Year ended
	30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	18,168	16,892	17,221	35,060	33,763	65,343
2 Other Income	454	523	194	977	431	1,268
3 Total Income (1+2)	18,622	17,415	17,415	36,037	34,194	66,611
4 Expenses						
(a) Cost of Materials Consumed	3,272	3,204	2,081	6,476	5,318	11,026
(b) Purchases of Stock-in-Trade	3,878	3,306	2,633	7,184	5,122	9,514
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(492)	(508)	703	(1,000)	478	861
(d) Employee Benefits Expense	3,616	3,370	3,309	6,986	6,583	12,614
(e) Finance Costs	12	13	17	25	32	62
(f) Depreciation and Amortisation Expense	522	514	531	1,036	1,060	2,143
(g) Other Expenses	3,991	3,973	3,902	7,964	7,762	15,363
Total Expenses	14,799	13,872	13,176	28,671	26,355	51,583
5 Profit before exceptional items and tax (3-4)	3,823	3,543	4,239	7,366	7,839	15,028
6 Exceptional items (Refer Note 3)	1,122	-	(2,730)	1,122	(2,730)	8,260
7 Profit before tax	4,945	3,543	1,509	8,488	5,109	23,288
8 Income tax expenses						
a. Current Tax	1,156	907	1,078	2,063	2,029	4,969
b. Deferred Tax	104	7	11	111	(16)	(5)
Total tax expenses	1,260	914	1,089	2,174	2,013	4,964
9 Profit for the period (7-8)	3,685	2,629	420	6,314	3,096	18,324
10 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(3)	(2)	3	(5)	5	(147)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	1	1	(1)	2	(2)	37
Other Comprehensive Income Net of Tax	(2)	(1)	2	(3)	3	(110)
11 Total Comprehensive Income for the period (9+10)	3,683	2,628	422	6,311	3,099	18,214
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
13 Other Equity						51,730
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):						
(a) Basic (in Rs.)	22.28	15.90	2.54	38.18	18.72	110.80
(b) Diluted (in Rs.)	22.28	15.90	2.54	38.18	18.72	110.80

SIGNED FOR IDENTIFICATION
BY
AK
S R B C & CO LLP
MUMBAI




Statement of Assets and Liabilities

(Rs. in Lakhs)

Particulars	As at September 30, 2025	As at March 31, 2025
	(Unaudited)	(Audited)
ASSETS		
Non-current assets		
Property, plant and equipment (Including Right of use assets)	15,889	16,118
Capital work-in-progress	2,739	395
Other intangible assets	780	1,065
Intangible assets under development	1,216	1,211
Financial assets		
i. Investments	101	101
ii. Loans	16	17
iii. Other financial assets	43	43
Current Tax asset (Net)	289	156
Deferred tax assets (Net)	-	100
Other non-current assets	708	50
Total non-current assets	21,781	19,256
Current assets		
Inventories	10,697	9,298
Financial assets		
i. Investments	9,172	12,590
ii. Trade receivables	11,878	8,676
iii. Cash and cash equivalents	2,070	2,870
iv. Bank balances other than (iii) above	11,110	11,091
v. Other financial assets	896	579
Other current assets	2,967	1,421
Total current assets	48,790	46,525
Total assets	70,571	65,781
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,323	1,323
Other equity	54,072	51,730
Total equity	55,395	53,053
Liabilities		
Non-current liabilities		
Financial liabilities		
i. Other financial liabilities	341	291
Provisions	455	454
Deferred tax liabilities (Net)	9	-
Total non-current liabilities	805	745
Current liabilities		
Financial liabilities		
i. Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	1,201	366
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	8,591	7,573
ii. Other financial liabilities	1,744	1,763
Provisions	1,722	670
Other current liabilities	732	1,611
Current tax liabilities (Net)	381	-
Total current liabilities	14,371	11,983
Total liabilities	15,176	12,728
Total equity and liabilities	70,571	65,781

SIGNED FOR IDENTIFICATION
BY
AK
S R B C & CO LLP
MUMBAI



Unaudited Statement of cash flows for the six months ended September 30, 2025

(Rs. in Lakhs)

	Particulars	For the period ended	For the period ended
		September 30, 2025	September 30, 2024
		Unaudited	Unaudited
A	Cash Flow from operating activities		
	Profit before income tax	8.488	5.109
	Adjustments for		
	Add/(Less) :		
	Depreciation and amortisation expenses	1.036	1.060
	Loss on account of fire incident / (Insurance proceeds). net	(1.122)	-
	Finance costs	25	32
	Loss on disposal of property, plant and equipment	-	(5)
	Unrealised exchange rate difference	(42)	(25)
	Provision for Doubtful Debts and Advances (Net)	(58)	(56)
	Interest received	(493)	(103)
	Gain on sale of investments	(330)	(211)
	Provisions no longer required and written back	-	(12)
	Net fair value gain on financial assets mandatorily measured at fair value through profit or loss	(82)	(75)
		7.422	5.714
	Working capital adjustments:		
	(Increase) in trade receivables	(3.093)	(3.649)
	Decrease in financial assets - Loans	1	2
	(Increase) / Decrease in other financial assets	(77)	(76)
	Decrease / (Increase) in other current assets	(1.546)	344
	Decrease / (Increase) in inventories	(1.399)	184
	(Decrease) / Increase in trade payables	1.842	(169)
	(Decrease) / Increase in other financial liabilities	(380)	(1.463)
	Increase / (Decrease) in provisions	110	155
	Increase / (Decrease) in other current liabilities	62	5.285
	Cash generated from operations	2,942	6,327
	Income taxes paid	(1.815)	(1.694)
	Net cash inflow from operating activities	1,127	4,633
B	Cash flow from investing activities		
	Acquisition of property, plant and equipment and Intangible assets	(3.197)	(2.420)
	Proceeds from sale of property, plant and equipment	-	7
	Interim payment received from insurance claim	960	-
	Movement in Other bank balances (Net)	(19)	-
	Investment in Mutual Funds	(1.000)	(2.150)
	Receipt from Sale of Mutual fund	4.830	2.261
	Interest received	493	103
	Net cash inflow/(outflow) from investing activities	2,067	(2,199)
C	Cash flow from financing activities		
	Interest paid	(25)	(32)
	Dividend paid	(3,969)	(2,646)
	Net cash (outflow) from financing activities	(3,994)	(2,678)
	Net (decrease)/increase in cash and cash equivalents	(800)	(244)
	Add: Cash and cash equivalents at the beginning of the financial period	2.870	1.972
	Cash and cash equivalents at the end of the period	2,070	1,728

SIGNED FOR IDENTIFICATION BY



S R B C & CO LLP
MUMBAI




Notes:

- The above unaudited financial results have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on October 17, 2025.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- Exceptional items: (Rs. in Lakhs)

Exceptional Income / (Expenses)	Quarter ended			Six month ended		Year ended
	30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Transfer charges towards assignment of portion of leasehold rights made in earlier periods under Urban Land (Ceiling and Regulation) Act, 1976	-	-	(2,730)	-	(2,730)	-
Profit on assignment of surplus vacant leasehold land along with built-up structures situated at MIDC, Navi Mumbai	-	-	-	-	-	9,893
Gain/(Loss) on account of fire incident - Refer note 3(a)	1,122	-	-	1,122	-	(1,633)
Total exceptional items	1,122	-	(2,730)	1,122	(2,730)	8,260

- 3(a) On January 2, 2025, a fire incident occurred at one of the manufacturing blocks of the API plant of the Company located at Plot No. 25/25A, MIDC Land, Thane-Belapur Road, Navi Mumbai – 400703, Maharashtra resulting in an impact on part of the Building, Plant & Machinery, inventories and other assets of the said manufacturing block. All the other manufacturing blocks on the site and buildings housing other departments viz. QC, QA, Engineering, Stores, R&D, etc. are unaffected and are functioning as usual. There was no casualty or loss of human life in this incident. The assets impacted due to the fire incident are adequately covered under an insurance policy. The Company has performed a comprehensive analysis of the estimated loss arising on account of the fire incident for majority of the assets impacted by the fire and accordingly submitted a provisional insurance claim for the estimated loss. Based on such assessment, the Company has so far recognised a loss of Rs. 2,561 lakhs (Rs. 2,483 lakhs for the year ended March 31, 2025 and Rs. 78 lakhs for the quarter and six months ended September 30, 2025). The insurance Company has acknowledged the claim and has so far released five tranches of interim payment aggregating Rs. 2,050 lakhs (Rs. 850 lakhs for the year ended March 31, 2025 and Rs. 1,200 lakhs for the quarter and six months ended September 30, 2025). The Company has netted off the payments received from the insurance Company with loss assessed due to damage caused by fire and the same is reflected under exceptional items for the respective periods. The net loss stands at Rs. 511 lakhs as on September 30, 2025 and the Company is confident of recovering this loss from the insurance company in subsequent quarters. The final amount of the approved claim from the insurance company will be determined based on the completion of the restoration activity of the said block, and additional net gain/loss, if any, would be accounted in subsequent quarters upon finalisation of such claim.



For RPG Life Sciences Limited

Ashok Nair

Ashok Nair
Managing Director
DIN: 07906710

Place: Mumbai
Date: October 17, 2025